The market for PEGylated proteins is expanding and changing dramatically due to advances in biotechnology, increased demand for innovative treatments, and rising infrastructure spending in the healthcare sector. This blog examines the market for PEGylated proteins, including its current state, major drivers, difficulties, and potential future developments.
The process of joining polyethylene glycol (PEG) chains to peptides or proteins is known as PEGylation. By enhancing the stability, solubility, and half-life of proteins and decreasing their immunogenicity and proteolysis, this modification improves the therapeutic qualities of proteins. PEGylated proteins are therefore frequently employed in a wide range of therapeutic applications, such as the treatment of chronic illnesses, cancer, and enzyme replacement therapies.
According to BCC Research, The global market for PEGylated proteins is expected to grow from $10.2 billion in 2023 and projected to reach $15.9 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.4% during the forecast period of 2023 to 2028.